Literature DB >> 18671260

Preliminary development of DNA aptamer-Fc conjugate opsonins.

John G Bruno1, Maria P Carrillo, Randy Crowell.   

Abstract

Encapsulated bacteria such as virulent strains of Bacillus anthracis impair phagocytosis with their capsules unless opsonized by antibodies. Poly-gamma-D-glutamic acid (gamma-PDGA) is the major component of the B. anthracis capsule. In this work, poly-alpha-D-glutamic acid (alpha-PDGA)-coated magnetic beads (MBs) were used as surrogates to simulate vegetative B. anthracis cells and avoid the hazards of working with virulent bacteria. DNA aptamers were developed against the alpha-linked PDGA-MBs and sequenced. Four of the most frequent candidate aptamer sequences in the pool were coupled at their 5' ends to Fc fragments of murine IgG to act as artificial antibodies. The effects of candidate aptamer-Fc conjugate addition on macrophage attachment and internalization of alpha-PDGA-MBs were tested on P388D1 and RAW 264.7 murine macrophage lines by spectrofluorometric and image analysis techniques. P388D1 cells were not able to internalize the alpha-PDGA-MBs, but attachment to alpha-PDGA-MBs was enhanced by the conjugates to varying degrees. Ingestion of alpha-PDGA-MBs by RAW 264.7 cells in the presence of several different candidate aptamer-Fc conjugates demonstrated a statistically significant (p < 0.01) increase in phagocytic index (P.I.) up to threefold in the first 30 min of exposure to alpha-PDGA-MBs. This preliminary study using alpha-linked instead of gamma-linked PDGA provides proof-of-concept for future work in the new area of hybrid DNA aptamer-protein constructs as potential opsonins. Copyright 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18671260     DOI: 10.1002/jbm.a.32182

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  11 in total

1.  Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.

Authors:  John Gordon Bruno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

2.  Discrimination of recombinant from natural human growth hormone using DNA aptamers.

Authors:  John G Bruno; Maria P Carrillo; Taylor Phillips; Allison Edge
Journal:  J Biomol Tech       Date:  2011-04

3.  Multivalent artificial opsonin for the recognition and phagocytosis of Gram-positive bacteria by human phagocytes.

Authors:  Kristy N Katzenmeyer; James D Bryers
Journal:  Biomaterials       Date:  2011-06       Impact factor: 12.479

Review 4.  Aptamer-Drug Conjugates.

Authors:  Guizhi Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2015-07-14       Impact factor: 4.774

Review 5.  Aptamers in the Therapeutics and Diagnostics Pipelines.

Authors:  Harleen Kaur; John G Bruno; Amit Kumar; Tarun Kumar Sharma
Journal:  Theranostics       Date:  2018-07-01       Impact factor: 11.556

6.  Selection of aptamers for a protein target in cell lysate and their application to protein purification.

Authors:  Sahar Javaherian; Michael U Musheev; Mirzo Kanoatov; Maxim V Berezovski; Sergey N Krylov
Journal:  Nucleic Acids Res       Date:  2009-03-20       Impact factor: 16.971

7.  A review of therapeutic aptamer conjugates with emphasis on new approaches.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2013-03-19

8.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

Review 9.  Potential Inherent Stimulation of the Innate Immune System by Nucleic Acid Aptamers and Possible Corrective Approaches.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2018-06-23

Review 10.  Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.

Authors:  John G Bruno
Journal:  Molecules       Date:  2015-04-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.